Diabetic kidney disease 2.0: the treatment paradigm shifts

Affiliations

Comment

Richard E Gilbert. Lancet Diabetes Endocrinol. 2019 Nov.

. 2019 Nov;7(11):820-821.

doi: 10.1016/S2213-8587(19)30253-0. Epub 2019 Sep 5.

¹ Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, ON M5B 1W8, Canada. Electronic address: richard.gilbert@utoronto.ca.

No abstract available

Comment on

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, Mahaffey KW, Charytan DM, Wheeler DC, Arnott C, Bompoint S, Levin A, Jardine MJ. Neuen BL, et al. Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-854. doi: 10.1016/S2213-8587(19)30256-6. Epub 2019 Sep 5. Lancet Diabetes Endocrinol. 2019. PMID: 31495651